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Drug therapyDyslipidaemia accelerates the atherosclerotic process and its morbid consequences; stat-
ins represent the evidence-based treatment of choice for reducing low-density lipoprotein
cholesterol levels and decreasing cardiovascular events. Unfortunately, statins are fre-
quently not available for several reasons, including intolerance, side effects or, simply,
patient preference. Nutraceuticals and functional food ingredients that are beneficial to
vascular health may represent useful compounds that are able to reduce the overall car-
diovascular risk induced by dyslipidaemia by acting parallel to statins or as adjuvants in
case of failure or in situations where statins cannot be used. The mechanisms underlying
such actions are not fully understood but may be related to reducing 7a-hydroxylase,
increasing faecal excretion of cholesterol, decreasing 3-hydroxy-3-methylglutaryl-CoA
reductase mRNA levels or reducing the secretion of very low-density lipoprotein. This
contribution provides an overview of the mechanism of action of nutraceuticals and
functional food ingredients on lipids and their role in the management of lipid
disorders.
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Dyslipidaemia is a main cardiovascular risk factor for coro-
nary heart disease (CHD) incidence and mortality, as already
demonstrated by several studies (Gillespie et al., 2012; Heron,
2012; Roger et al., 2012). Lipid disorders can accelerate the
atherosclerosis process and its consequences, such as heart
failure and coronary atherosclerosis (Ebong et al., 2013;
Paramsothy et al., 2010), whereas the control of fasting lipid
blood levels leads to a reduction in the cardiovascular risk
profile of individuals (Cziraky et al., 2011).
Nevertheless, failure to achieve an optimal reduction of li-
pid levels can often be observed in real life. Martin et al. (2013)
recently noted that patients with acute myocardial infarction
(AMI) often failed to reach the target level of low-density lipo-
protein (LDL)-cholesterol <100 mg/dL at 6-month follow-ups
after discharge from the hospital. Among their 336 AMI pa-
tients, 33% (n = 121 patients) did not attain the lipid levels
goal, and this was due to the absence of statin therapy pre-
scription at discharge, reduced adherence to therapy, lack of
cardiac rehabilitation participation and/or diet/activity coun-
selling. Many other studies have confirmed the previous find-
ings (Collins & Altman, 2012; Ludman et al., 2011; Pittman
et al., 2012).
Thus, other interventions had already been considered to
promote healthy control of dyslipidaemia. In 1989, DeFelice
hypothesised the occurrence of biological interventions not
related to pharmacological methods and wrote about ‘‘nutra-
ceutical’’ products, i.e., ‘‘a food (or part of a food) that provides
medical or health benefits, including the prevention and/or treat-
ment of a disease’’ (DeFelice, 1995; Kalra, 2003). The original
hypothesis was that these foods can protect human body
from adverse events because of the beneficial effects of some
phytochemicals. Several studies have reported the validity of
this idea in clinical practice (Estruch et al., 2013; Massaro
et al., 2010). In particular, the Mediterranean diet, which
may be considered on top of the list, can improve the overall
outcome and prognosis of the general population by reducing
major cardiovascular risk events (myocardial infarction,
stroke, or death from cardiovascular causes) rates (Estruch
et al., 2013). This positive action may be related to several
mechanisms such as endothelial function amelioration
(Zuchi et al., 2010), atherosclerosis burden reduction
(Badimon, Vilahur, & Padro, 2010), antithrombotic activities
(Chakrabarti & Freedman, 2010), decreases in diabetes and
metabolic syndrome incidence and evolution (Davı`, Santilli,
& Patrono, 2010) and improving dyslipidaemia (Houston,
2012) via lipid metabolism mechanisms (such as improving
paraoxonase activities) (Rahimi-Ardabili et al., 2012).The present contribution provides a detailed overview of
nutraceutical action on dyslipidaemia to highlight the role
of functional food ingredients in overcoming the negative ef-
fects of lipid disorders beyond pharmacological interventions.
2. Methods
The database consulted was MEDLINE. The main keywords
adopted were nutraceuticals, functional foods, dyslipida-
emia, hypercholesterolaemia, cardiovascular diseases and
cardiovascular mortality/morbidities. All terms were com-
bined to obtain the maximum selection of relevant articles.
One physician analysed all the studies from MEDLINE, com-
bining each term to generate a complete overview of the lit-
erature. The period considered was from 1989 until
November 2013. More than 454 studies were evaluated; they
were collected according to aims, and the more relevant
studies (according to the population considered, the strength
of the results and the relationship with paragraph aims)
were included in the final version. Duplicates and ongoing
trials were excluded from the analysis. At the end, consider-
ing reviews and original articles involving children and ado-
lescents, only 104 articles were considered for the final
evaluation (Fig. 1). All the main features of animals and hu-
man studies considered in this overview are summarised in
Tables 1 and 2.
3. Nutraceuticals: definition and classification
According to DeFelice’s definition, a ‘‘nutraceutical’’ is ‘‘a food
(or part of a food) that provides medical or health benefits, including
the prevention and/or treatment of a disease’’, as already noted
(DeFelice, 1995; Kalra, 2003). The term is tightly related to
‘‘functional food’’, defined by the US Institute of Medicine’s
Food and Nutrition Board as ‘‘any food or food ingredient that
may provide a health benefit beyond the traditional nutrients it con-
tains’’ (Ross, 2000). These are broad and not specific defini-
tions that include a myriad of compounds that are more or
less widespread in common diets.
The Bureau of Nutritional Sciences of the Food Directorate
of Health Canada (Health Canada, 1998) tried to provide more
accurate definitions of both nutraceuticals and functional
foods:
 Nutraceutical: ‘‘a product isolated or purified from
foods that is generally sold in medicinal forms not
usually associated with food. It is demonstrated to
have a physiological benefit or provide protection
against chronic disease.’’
Fig. 1 – Study flow chart.
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be, a conventional food, consumed as part of a usual
diet, and demonstrated to have physiological benefits
and/or reduce the risk of chronic disease beyond basic
nutritional functions.’’Because of the large number of compounds, it is quite
difficult to classify all nutraceuticals in a systematic manner.
Singh and Sinha (2012) attempted to order and classify
them. We attempt to offer a schematic approach to nutraceu-
tical classification in Fig. 2. At a glance, we can divide
Table 1 – Features of the main literature of in vivo/in vitro experimental researches about nutraceuticals.
Source N. Pts Nutraceutical Approach used Aims Results Time
Kumar et al. (2012) 15 Mice/130 embryos 8 week old Zinc Three groups: (a) control,
(b) diabetes, and (c)
diabetes + zinc (5 mg/
kg body weight).
Protective role of zinc on
diabetic embryonic rat
cardio-myoblast cells
Both cytosolic and mitochondrial
SOD activity was lower in embryos
from the diabetic group than control
and zinc-supplemented groups. Zn
inhibited oxidative stress- induced
damage and inhibition of ROS
generation
N/A
Kukongviriyapan
et al. (2012)
Male ICR mice 6–8 week old Quercetin Quercetin (50 or 100 mg/
kg) administered before
or after LPS (10 mg/kg;
i.p.) injection.
Antioxidant effects of
quercetin on LPS-induced
oxidative stress
Quercetin preserved vascular
function, blood pressure, heart rate
and vascular responsiveness to
stress. It up-regulated eNOS
expression, reduced oxidative stress,
and maintained blood glutathione
redox ratio
N/A
Chen et al. (2012) 30 Male C57BL/6J mice 38-week-old Resveratrol Three groups: (1) ND; (2)
HFD; (3)
HFD + resveratrol
(200 mg/kg diet/day)
Resveratrol influence on
hypercholesterolemia,
hepatic cholesterol
accumulation and bile acid
synthesis in vitro/vivo.
Resveratrol-fed mice had lower TC
and LDL-C, higher HDL-C, lower LDL-
C/HDL-C ratio than HFD group;
hepatic accumulation of cholesterol
was reduced by 46% compared with
HFD group (p < 0.05). CYP7a1 mRNA
and protein levels and enzyme
activity in liver from resveratrol-
treated mice were higher than ND
and HFD groups
8 weeks
Kato et al. (2009) 48 Female Wistar rats 6 month old Water-insoluble fish
protein
Rats subjected to sham-
operation or
ovariectomy, and fed
casein or IFP as a protein
source
IFP from Alaska pollock
(Theragra chalcogramma)
influence on
hypercholesterolaemia
related to ovarian hormone
deficiency.
IFP diet significantly decreased TC,
VLDL, LDL-C levels and 3-hydroxy-3-
methylglutaryl-CoA reductase
protein mRNA in the ovariectomised
rats
4 weeks
Quesada et al.
(2012)
Male Wistar rats N/A Grape seed
proanthocyanidin
extract
Two groups: (1) GSPE fed
rats (250 mg/kg body
weight); (2) control rats
GSPE
hypotriacylglycerolaemic
action
GSPE markedly reduced plasma TG
(22% reduction in the area under the
curve) 1.5 h after administration.
GSPE reduced chylomicrons/VLDL
content of TG and inhibited (30%)
VLDL-TG secretion
N/A
Quesada et al.
(2009)
12 Female rats N/A Grape seed
proanthocyanidin
extract
Three groups: (1)
GSPE + HFD (25 mg/kg of
body weight); (2) HFD; (3)
controls
GSPE effects in dyslipidemia
induced by HFD
GSPE decreased TG (204.0 ± 2.3 vs
129.4 ± 12.3 mg/dL, p < 0.05) and LDL-
C (15.2 ± 2.0 vs 6.6 ± 1.0 mg/dL,
p < 0.05) than HFD rats and improved
HDL-C/LDL-C ratio
13 weeks
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iges et al. (2010) 18
Female
Wistar
rats
N/A Grape seed
proanthocyanidin
extract
Three groups: (1) GSPE + HFD
(25 mg/kg of body weight); (2)
HFD; (3) controls
GSPE effects on the liver
proteome of rats
suffering from metabolic
syndrome
Protein exhibited similar expression
in the FD + GSPE and control
groups thus GSPE corrected HFD
effects Some of these proteins are
related o lipid metabolism (pyruvate
kinase TP-citrate lyase isoform 1;
fatty-a d synthase; glycerol-3-
phosp te dehydrogenase 1;
mitoch ndrial acyl-CoA thioesterase
2 and tyryl-CoA synthetase 1
protein
13 weeks
shatwi et al.
011)
42 Male
Wistar
rats
8 week
old
Black/green tea Six groups: (I) ND; (II) HCD;
(III) ND + black tea (7 g/L); (IV)
HCD + black tea (7 g/L); (V)
ND + green tea (7 g/L); (VI)
HCD + green tea (7 g/L)
Effect of black or green
tea on lipid status and
lipid peroxidation
Group I/V had decreased (p < 0.001)
TC and DL-C. Group V rats showed a
TG (p < .001) and TC/LDL-C (p < 0.01)
decrea and HDL-C increase
(p < 0.0 ) than group III. Group VI
showe a decrease in TC, TG, and
LDL ch lesterol (p < 0.001) and an
increa (p < 0.01) in HDL-C, HCD
group. roup VI showed a decrease in
TC/TG < 0.001) and LDL-C (p < 0.01),
an HD C increase (p < 0.05) than
group
5 weeks
uang and Lin
012a)
30 Male
Wistar
rats
5 week-
old
Green, oolong, black
and pu-erh teas.
Six groups: (1) C: chow; (2) F:
fructose + chow; (3) FG:
fructose + chow + green tea;
(4) FB:
fructose + chow + black tea;
(5) FO:
fructose + chow + oolong tea;
6) FP: fructose + chow + pu-
erh tea
Green, oolong, black and
pu-erh teas effects on
dyslipidaemia
Green, olong, black and pu-erh teas
signific ntly reduced serum TG (FG:
80.1 ± .1 mg/dL; FB: 92.3 ± 26.4 mg/
dL; FO 7.6 ± 23.1 mg/dL; FP:
66.8 ± .1 mg/dL) than group F
(175.4 24.6 mg/dL; p < 0.05). Green,
black a d pu-erh teas significantly
reduce serum TC (FG: 59.1 ± 3.6 mg/
dL; FB: 7.7 ± 3.4 mg/dL; FP:
67.8 ± 0 mg/dL) than group F
(75.3 ± .9 mg/dL; p < 0.05). Green,
oolong black and pu-erh teas
norma zed the serum TG and TC
concen rations
12 weeks
en et al. (2008) Male
Wistar
rats
6–8
week
old
Red mold rice (RMR) (I) Control; (II) HFD; (III)
HFD + 1.43 mg/kg/day
lovastatin; (IV) HFD + 0.4%
rice; (V) HFD + 0.4% RMR; (VI)
HFD + 2% RMR
Influences of red mold
rice (RMR) on obesity,
dyslipidaemia and
related metabolic
abnormalities
RMR s nificantly reduced serum TC,
LDL-C, DL HDL-C ratio in the HFD
group. he HFD + 2% red mold rice
protoc significantly increased
serum DL-C
6 weeks
(continued on next page)
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Table 1 – (continued.)
ource N. Pts Nutraceutical Approach used Aims Results Time
vir et al. (2009) 24 Male
Sprague-
Dawley
rats
N/A Algal biomass and
isolated algal
polysaccharide of
Porphyridium sp.
Four groups: (1) algal
biomass fed; (2) algal
polysaccharide fed; (3)
pectin-fed; (4) control
Algal biomass and
isolated algal
polysaccharide (AP) of
Porphyridium sp. effects
in hypercholesterolemic
rats
Biomass or AP significantly reduced: TC
(22–34%; p < 0.001), TG and VLDL-C v (12–
39%) and LDL-C (32–53%; p < 0.005)
compared with control or pectin-fed rats.
HDL/LDL-C ratio was higher (31–60%;
p < 0.001) in the AP and biomass groups vs.
the pectin and control diets
15 days
etzger et al.
2009)
54 Swine 6-month old Pectin, polyphenols,
phytosterols
Treatment diets (pectin,
polyphenols, phytosterols,
all combinations of pectin,
polyphenols, and
phytosterols) vs lovastatin vs
controls
To compare nutritional
supplements (pectin,
polyphenols, and
phytosterols) to
lovastatin to reduce
serum cholesterol
All, except pectin, reduced TC more than
control/lovastatin. LDL-C was reduced 22%,
19%, 20%, 17%, 18%, and 17% by
polyphenols, phytosterols,
pectin + polyphenols,
pectin + phytosterols,
polyphenols + phytosterols, and
pectin + polyphenols +
phytosterols, respectively, compared to
control (8%) and lovastatin (40%)
8 weeks
ang (2010) 48 Male
Wistar
rats
32-month-old Powder of mulberry
(Morus alba L.) fruit
Six groups: (1) ND: normal
diet; (2) NDM I: ND + 5% MFP;
(3) NDM II: ND + 10% MFP; (4)
HFD; (5) HFM I: HFD + 5%
MFP; (6) HFM II: HFD + 10%
MFP
Hypolipidaemic and
antioxidant effects of
MFP in hyperlipidaemic
rats
HFM II group showed a decrease of 16.2%
for TC, 35.7% for TG, 23.5% for LDL-C and
43.4% for AI compared than HF. Liver TC
decreased by 17.0% and liver TG by 54.3%,
while HDL-C increased by 33.0%. HFM I did
not show significantly differences than HF
group, except for serum TG (18.6%
decrease).
4 weeks
remer et al,
2013), in press
19 Rhesus
monkeys
12–20 years Fish oil Two groups: (1) standard
chow plus 75 g fructose/day
(control); (2) standard chow,
75 g fructose/day, and 4 g fish
oil (16% EPA/11% DHA)/day
Evaluate the effects of
fish oil on dyslipidaemia
Fasting TG and apo CIII concentrations
higher in controls than patients (p = 0.005).
Controls showed an increased fasting TG
(+71 ± 25%) and apo CIII (+28 ± 8%), while
no change was detected in daily fish oil
supplemented patientsCholesterol
concentrations increased slightly in the
control group (+4 ± 3%), while decreasing in
treated one (-8 ± 5%) (P = 0.025).
6 months
uff et al. (1992) 6
Miniature
pigs
N/A Fish oil Crossover design: first diet
containing fish oil 30 g/day
for 3 weeks; then of
lovastatin 1.2 mg/kg body
weight/day for a further
3 weeks
Effect of Lovastatin to
the fish oil diet
combination to lipids
Combined therapy reduced VLDL apo B
production (26%, p < 0.005). Conversion of
VLDL apo B to LDL was reduced by 48%
(p < 0.005), It determined a 38% (p < 0.002)
decrease in LDL production
6 weeks
akutsu et al.
2012)
16 KKAy
mice
5 week old Fish oil Three groups: (1) beef tallow
diet ad libitum (BA); (2) beef
tallow diet restricted (BR); (3)
fish oil diet; (4) controls
Effects of fish oil on
lipids levels
TG and TC plasma as well as liver
concentrations tended to decrease in obese
KKAy mice fed fish oil. A reduced
expression of fatty acid synthase mRNA
was noticed in fish oil mice as compared to
controls
6 weeks
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Gunathilake et al.
(2013)
60 Male
rats
N/A Polyphenols-rich
fruit-based
functional beverage
Five groups: normal control; HFD;
and HFD with three different
beverage dosages (0.5X, 1X, 2X),
where X is the equivalence of
two portion sizes for an adult
(X = 10 ml/kg body weight/day)
after dose translation
Polyphenols-rich fruit-based
functional beverage action
on serum and liver lipid
profiles in vivo
Rats treated with 1X or 2X had
significantly (p < 0.05) lower total and free
cholesterol levels than HFD alone group
and than group fed with 0.5X
1X and 2X supplementation doses
reversed the serum lipid as compared to
HFD alone treated
4 weeks
Jin et al. (2013) 40 Male SD
rats
4-week-old Theaflavins
(polyphenols)
Five groups: (1) ND; 2) HFD; (3)
HFD + BTE; (4) HFD + TFs; (5)
HFD + TF1
Evaluate theaflavins effects
on lipid levels.
TC levels in the HFD + TFs group was
reduced by 26.5% (i < 0.05). BTE, TFs and
TF1 significantly reduced TG by 56.9%,
50.8% and 52.3% as compared to HFD
control group, respectively (p < 0.05).
They BTE, TFs and TF1 decreased LDL-C
by 69.6%, 71.7% and 43.5%, respectively,
as compared to HFD controls (i < 0.05)
30 days
Kwok et al. (2013) 32 Male
Sprague–
Dawley
rats
N/A Ethanolic extract of
dried fruit of
Crataegus pinnatifida,
hawthorn (Shan
Zha)
Four groups: (1) control; (2) HCD;
(3) low dose Shan Zha 80%
ethanolic extract (30 mg/kg/day,
p.o.) (HCD + SA); (4) high dose
Shan Zha 80% ethanolic extract
(100 mg/kg/day, p.o.) (HCD + SB)
Evaluate Crataegus
pinnatifida, hawthorn (Shan
Zha) on cholesterol plasma
concentrations
SA/SB suppress the increased plasma TC
(p < 0.05) and LDL-lipoprotein (p < 0.05)
induced by the HCD. Liver lipids
increased (p < 0.001) in the HCD,
HCD + SA and HCD + SB groups as
compared to controls. SB significantly
enhanced the suppressed mRNA
expression level up to about 90% of the
Control level (p < 0.05)
4 weeks
Hsu et al. (2013) 32 Syrian
golden
hamster
6-weeks old Ankaflavin Four groups: (a) normal diet
(control); (b) HFD; (c) HFD + AK
(5 mg/kg body weight/day); and
(d) HFD + AK + GW9662 (PPARc
antagonist; 5 mg/kg body weight/
2 days
Potential mechanism of AK-
regulated dyslipidaemia.
AK was found to suppress increases in
plasma TC levels in HFD hamsters.
6 weeks
Srinivasan and
Pari (2013)
24 Male
albino
Wistar rats
N/A Diosmin Four groups: (1) controls; (2)
normal rats + diosmin (100 mg/
kg b.w.; (3) diabetic; (4) diabetic
rats + diosmin (100 mg/kg body
weight
Investigate
antihyperlipidemic effects of
diosmin
Diosmin significantly (p < 0.05) reduced
cholesterol, TG, free fatty acids and
phospholipids in plasma and tissues as
compared to diabetic rats
It decreased VLDL and increased HDL
levels (p < 0.05)
It significantly (p < 0.05) decreased the
activity of 3-hydroxy 3-methylglutaryl
coenzyme A as compared to diabetic
control rats
45 days
AK: ankaflavin; BTE: black tea extract; CYP7a1: cholesterol 7a-hydroxylase; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; GSPE: grape seed proanthocyanidin extract; HCD: high-
cholesterol diet; HDL-C: high-density lipoprotein-cholesterol; HFD: high fat diet; IFP: water-insoluble fish protein; LDL-C: low-density lipoprotein-cholesterol; LPS: lipopolysaccharide; MFP: powder of
mulberry fruit; N/A: not applicable; ND: normal diet; RMR: red mold rice; ROS: reactive oxygen species; SOD: superoxide dismutase; TC: total cholesterol; TF1: theaflavin; TFs: theaflavins mixture; TG:
triglycerides; VLDL-C: very low density lipoprotein-cholesterol.
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Table 2 – Features of the main literature studies involving humans about nutraceuticals role in dyslipidaemia treatment.
Source N. Age
(years)
Design Nutraceutical Approach used Aims Results Time
Estruch et al.
(2013)
7447 55–80 Parallel-group,
multicenter,
randomized trial
Mediterranean diet
supplemented with
extra-virgin olive oil or
nuts
Three groups:
 Mediterranean
diet + extra-vir-
gin olive oil
 A Mediterranean
diet + nuts
 Controls
Mediterranean diets (+ extra-
virgin olive oil or nuts) efficacy
on primary cardiovascular
prevention
Primary end-point events
occurred in 288 participants. The
multivariable-adjusted hazard
ratios for primary endpoints
were 0.70 (95% CI, 0.54 to 0.92)
and 0.72 (95% CI, 0.54–0.96) for
extra-virgin olive oil and nuts
groups. Mediterranean diet
reduces incidence of major
cardiovascular events
4.8 years
Rahimi-Ardabili
et al. (2012)
60 N/A Double-blind
randomized
controlled trial
Zinc 100 mg/day zinc vs
placebo
Effects of zinc supplementation
on PON enzyme activity
No change were in TC, TG, LDL-C,
and Apo-B levels. HDL-C, Apo-AI,
and PON activity were
significantly increased (p = 0.02)
than controls
2005–2007
Sheikholeslami
Vatani and
Ahmadi Kani
Golzar (2012)
30 23.4 ± 3.6 Single-blind
research protocol
Whey Three groups: (1)
resistance
training + whey (RW);
(2) resistance
training + placebo; (3)
control group
Effects of whey protein
supplementation and resistance
training in overweight young
men
In the post-test TC decreased
significantly only in the RW
group (p < 0.05). HDL-C levels
increased significantly in the RW
group pretest to post-test
(p < 0.05). LDL-C/TG decreased in
experimental groups in the post-
test (p < 0.05).
6 weeks
Marazzi et al.
(2011)
80 82.4 ± 4.4 Randomize,
prospective,
parallel group,
single-blind
Berberine, policosanol,
red yeast rice, folic acid,
coenzyme Q10,
astaxanthin
Nutraceutical-
combined pill
(berberine 500 mg,
policosanol 10 mg, red
yeast rice 200 mg, folic
acid 0.2 mg, coenzyme
Q10 2.0 mg, and
astaxanthin 0.5 mg) vs
placebo
Nutraceuticals effects in elderly
hypercholesterolemic patients
(>75 years of age) previously
intolerant to statins and refusing
other pharmaceutical treatments
TC (20%, p < 0.001) and LDL-C
(31%, p < 0.001) decreased
significantly in the treated group;
no significant change in placebo
group; significant between-group
differences (p = 0.008 and
p = 0.002,respectively)
No significant changes for
plasma HDL cholesterol
12 months
Tome´-Carneiro
et al. (2012)
75 62 ± 9 Triple-blind,
randomized,
placebo-
controlled trial
Grape seed
proanthocyanidin
extract and resveratrol
Three groups: (1)
resveratrol-enriched
grape extract (GE-RES);
(2) grape extract (GE);
(3) placebo
(maltodextrin).
Effect of GSPE plus resveratrol on
statin-treated patients in
primary cardiovascular disease
prevention
GE-RES decreased ApoB
(9.3 mg/dL, 95% CI 16.4, 2;
p = 0.014), LDLox (14.5 U/L, 95%
CI 19.5, 9.5; p = 0.001), LDLc
(5 mg/dL, 95% CI 14, 4;
p = 0.04), LDLox/ApoB (0.01 U/
mg, 95% CI 0.015, 0.005;
p = 0.000), while increased non-
HDL-C/ApoB ratio (0.12, 95% CI
0.04, 0.13; p = 0.046)
6 months
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Qin et al. (2009) 120 40–65 Double-blind,
randomized,
placebo-
controlled trial
Anthocyanin Two groups: (1) anthocyanin
(two 80-mg anthocyanin
capsules twice daily); (2)
placebo (2 capsules twice daily)
Effects of pure
anthocyanins on the
serum lipid profile in
dyslipidemic patients
Anthocyanin creased HDL-C [13.7% (95% CI:
10.4%, 16.9%) s 2.8% (95%CI: 21.6%, 7.2%),
p < 0.001] and ecreased LDL-C [13.6% (95%
CI: 10.1%, 17.1 vs +0.6% (95% CI: 24.1%, 5.2%),
p < 0.001] com ared to controls [between
group differe e: p < 0.001]. Anthocyanin
decreased CE mass [10.4% (95% CI: 6.7%,
14.1%) vs +3.5 (95% CI: 23.6%, 10.5%)]
compared to ntrols [between group
difference: p 0.001]
CETP activity ecreased in the anthocyanin
group than co trol [6.3% (95% CI: 4.6%, 8.0%)
vs 1.1% (95% : 21.6%, 4.0%), p = 0.001]. In the
anthocyanin oup, HDL-C change was
negatively co elated with CETP activity
change (rs = 2 .330, p = 0.010); LDL-C change
was positivel correlated with CETP mass
change (rs = 0 54, p = 0.005)
04/2007–10/2008
Becker et al.
(2009)
62 60.5 ± 9.3 Randomized,
controlled trial
Red yeast rice /
RYR)
Two groups: (1) RYR, (1800-mg/
day); (2) placebo
RYR in dyslipidemia in
statin-intolerant patients
LDL-C decrea d from baseline in RYR group
[27.3 ± 16.4% at week 12 and 21.3 ± 22.7%
at week 24]. L L-C significantly differed
between the R and placebo groups (week
12: p < 0.001; eek 24: p = 0.011) as well as TC
(week 12: p < 001; week 24.p = 0.016)
09/2006–03/2007.
Rayman et al.
(2011)
501 60–74 Double-blind,
placebo-
controlled, study
Selenium. Four groups: (1) placebo; (2)
100 mcg selenium/day; (3)
200 mcg selenium/day; (4)
300 mcg selenium/day
Selenium
supplementation action
on TC, HDL and non-HDL-
C
In longitudin analyses, selenium decreased
TC, non-HDL levels, and TC/HDL-C ratio,
with increasi HDL-C levels
06/2000–07/2001
Wofford et al.
(2012)
352 >22 Randomized
double-blind, 3-
phase crossover
trial
Soy protein
and milk
protein
Three sequences:
(A) soy protein!milk
protein! complex
carbohydrate;
(B) milk
protein! carbohydrate! soy
protein;
(C) carbohydrate! soy
protein!milk protein
Effects of soy protein, milk
protein and complex
carbohydrate
supplementations on
serum lipids and
lipoproteins
Soy protein re uced TC by 3.97 mg/dL (95% CI,
7.63 to 0.3 p = 0.03) and TC/HDL-C ratio
by 0.12 (95% C , 0.23 to 0.01; p = 0.03)
compared wi carbohydrate-
Soy protein in reased HDL by 1.54 mg/dL (95%
CI, 0.63 to 2.4 P = 0.0009) and reduced TC/
HDL-C ratio b 0.14 (95% CI, -0.22 to -0.05;
P = 0.001) com ared with milk protein.
09/2003–04/2008
Wong et al.
(2010)
23 59.6 ± 7.7 Randomized
controlled
crossover trial
Soy protein
and probiotics
Three groups: (1) prebiotic
alone; (2) soy plus prebiotic; (3)
soy without prebiotic
Soy and a prebiotic
influence on serum lipid
Soy + prebioti reduced LDL-C
(0.18 ± 0.07 mmol/L, p = 0.042), LDL-C/HDL-C
(0.28 ± 0.11, = 0.041), TC/HDL-C
(9.2% ± 2.7% p = 0.004), LDL/HDL-C
(12.2% ± 3.4 p = 0.003), while increased
HDL-C (0.06 ± .02 mmol/L, p = 0.029) more
than prebioti
09/2003–03/2004
(continued on next page)
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Table 2 – (continued)
Source N. Age
(years)
Design Nutraceutical Approach used Aims Results Time
Casas-
Agustench et al.
(2012)
43 49 ± 13 Randomized
placebo-
controlled,
crossover study
Plant sterol esters Three groups: (1)
placebo (skimmed
milk, SM); (2) plant
sterol-enriched
skimmed milk (PS-SM);
(3) plant sterol-
enriched semi-
skimmed vegetable
fat-enriched milk (PS-
VFM.
PS esters and vegetable fat in
hypercholesterolaemic subjects
PS-SM and PS-VFM reduced TC
and LDL-C (p < 0.015) by 7.8% and
6.3% and by 8.0% and 7.4%,
respectively. HDL-C rose by 3.8%
with PS-VFM milk (p < 0.05)
compared to PS-SM milk. TG
decreased by 18Æ7% in PS-VFM
group (p < 0.01) than PS-SM
16 weeks
Demonty et al.
(2006)
21 30–65 Semi-
randomized,
single-blind, 4-
period crossover
study
Fish-oil fatty acid esters
of plant sterols (FO-PS)
Three treatment:
(1) Fish oil
(2) Fish oil
+ FO-PS
(3) Low-fat SU-PS
margarine
Effect of fish-oil supplement
containing PS esterified to fish-
oil fatty acids on the lipid profile
of overweight, hyperlipidemic
subjects
FO-PS and SU-PS reduced LDL-C
(p = 0.0031 and 0.041,
respectively) more than controls.
Fish oil and FO-PS resulted in TG
levels 40% (p = 0.0004) and 46%
(p = 0.0002) lower, respectively,
than controls ones. FO-PS and
fish oil resulted in TG levels 39%
(p < 0.0001) and 32% (p = 0.0001)
lower, respectively, than SU-PS
8 weeks
Gonc¸alves et al.
(2006)
37 30–45 Crossover study Plant sterol-enriched
milk
Two groups: (1) PS-
enriched milk (2 mg/
day); (2) controls (milk
without PS)
Effect of PS milk in
hypercholesterolemia
TC decreased from 245 to
223 mg/dL after 15 days of PS-
milk intake and from 248 to
229 mg/dL after 30 days (p < 0.05),
as well as LDL-C (from 156 to
138 mg/dL after 15 days and from
157 to 143 mg/dL after 30 days,
p < 0.05)
30 days
Guardamagna
et al. (2011)
58 8–16 Open-label
intervention
study
Plant sterols Children evaluated
before and after a 12-
week treatment with
PS
PS effects in children with
different forms of primary
hyperlipidemias
PS significantly decreased in TC,
LDL-C and apoB. LDL-C
decreased about 15% in Familial
Combined Hyperlipidemia and
Undefined Hypercholesterolemia
children; about 10% in familial
hypercholesterolemia patients
12 weeks
Garaiova et al.
(2013)
25 16 Crossover study Plant sterols, fish oil and
B vitamins
Children evaluated
before and after PS
esters (1300 mg), fish
oil, vitamins B12
(50 lg), B6 (2.5 mg),
folic acid (800 lg) and
coenzyme Q10 (3 mg)
use
Effects of a combination of PS,
fish oil and B vitamins on lipids
profile of hypercholesterolemic
children and adolescents
TC, LDL-C, VLDL-C, subfractions
LDL-2, IDL-1, IDL-2 and plasma
homocysteine levels were
significantly reduced at the end
of the intervention period
(p < 0.05)
16 weeks
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aki et al. (2012) 32 21–79 Randomized
placebo-
controlled,
crossover trial
Plant sterols and stanols Treatment period I:
5 weeks, non-esterified
sterol/stanol tablets,
0.45 g per tablet) vs
placebo. Treatment
period II: 6 weeks,
cross over to receive
the opposite product
PS and stanols action in primary
hypercholesterolaemia
LDL-C (2 4.9%), non-HDL-C (2 3.6%)
and TC (2 2.8%) significantly
decreased after plant sterol/stanol
administration (p < 0.05).
11 weeks
ao et al.
011)
82 35–70 Randomized
crossover trial
Plant sterols Patients consuming
spreads with or
without 2 g/d of PS for
two 4-week periods,
each separated by a 4-
week washout
PS action in individuals with high
versus low basal circulatory PS
concentrations
Cholesterol absorption index was
positively correlated with
campesterol (r = 0.5864, p < 0.0001)
and b-sitosterol (r = 0.4676,
p < 0.0001) one. PS reduced
absorption indices of campesterol,
b-sitosterol, and cholesterol by
36.5 ± 2.7%, 39.3 ± 2.9%, and
34.3 ± 1.9%, respectively, but
increased cholesterol fractional
synthesis rate by 33.0 ± 3.3%
relative to control
12 weeks
lin et al.
006)
40 47.4 ± 10.8 Double-blind,
randomized
controlled trial
Sugar cane–derived
policosanol
Two groups: (1) oral
policosanol (20 mg)
once daily; (2) placebo
Sugar cane–derived policosanol
in mildly hypercolesterolemic
patients
No change was in LDL-C, HDL-C,
TG between groups
No change wad in LDL particle
number, LDL particle size, or any
other lipoprotein variable
01/2005–06/2005
cker et al.
008)
74 55.9 ± 8.4 Randomized
primary
prevention trial
Red yeast rice Group 1: simvastatin
(40 mg/d) group
Group 2: fish oil and
RYR.
RYR + fish oil vs statin in lipid
lowering therapy
LDL-C significantly decreased in
both groups but no significant
differences were noted between
groups. Groups 2 showed a more
pronounced decrease in TG (29%
vs 9.3%; 95% confidence interval,
61 to 11.7; p = 0.003) than
simvastatin group
05/2006–06/2006
nahi et al.
011)
100 52.9 ± 7.8 Randomized
open-label,
clinical trial
Heracleum persicum Group 1): H. persicum
(500 mg/
day) + atorvastatin
(10 mg/day); Group 2)
atorvastatin alone
(20 mg/day)
Heracleum persicum influence on
atorvastatin therapy in
dyslipidemic subjects
TC and LDL-C reduced both in the
H. persicum (p = 0.001) and
atorvastatin (p < 0.001) groups
No HDL-C, not TG change in the
H. persicum group
(p > 0.05).Atorvastatin alone was
not superior to combination
therapy in lipid lowering therapy.
06/2009–06/2010
ys et al. (2012) 177 53.2 ± 9.0 Randomized
placebo-
controlled, study
Icosapent ethyl Three groups: (1) IPE
4 g/day; (2) IPE 2 g/day;
(3) placebo
Effects of IPE on lipoprotein
particle concentration and size
IPE 4 g/day reduced large VLDL
(27.9%; p = 0.0211), total LDL
(16.3%; p = 0.0006), small LDL
(25.6%; p < 0.0001), total HDL
(7.4%; p = 0.0063) levels, and VLDL
particle size (8.6%; p = 0.0017)
12 weeks
(continued on next page)
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Table 2 – (continued)
Source N. Age
(years)
Design Nutraceutical Approach used Aims Resul Time
Chan et al.
(2002)
52 53 ± 1 Randomized,
placebo-
controlled, 2 · 2
factorial
intervention trial
Fish oil Two groups: (1) atorvastatin
(40 mg/day); (2) fish oil (4 g/
day)
Effects of fish oil on plasma lipids
and lipoproteins
Fish o significantly decreased TG
(0Æ38 0Æ11 mmol/L, p = 0.002) and increased
HDL-C (+0Æ07 ± 0Æ04 mmol/L, p = 0.041). No
signifi nt interactions were between
atorva tatin and fish oil treatments
6 weeks
Khandelwal
et al. (2013)
200 35–55 Double-blind,
placebo-
controlled, trial
Fish oil and
Plant sterols
Four groups: (1) both placebo;
(2) active omega-3; (3) active
plant sterol; (4) both active
Effects of omega-3 fatty acids
from fish oil and PS on LDL-C and
non-HDL-C levels
PS sig ificantly decreased LDL-C 4.5%;
p = 0.0 7) and non-HDL-C (7.9%; p = 0.0019)
levels. o effects were detected for fish oil
omega 3 fish oil
4 weeks
Oelrich
(2013)
57 52 ± 10 Double-blind,
parallel design,
placebo
controlled trial
Fish oil Four groups: (1) placebo; (2)
fish oil 4 g/day of combined
EPA and DHA provided as
90% TG formulation (TG90);
(3) fish oil 4 g/day of
combined EPA and DHA
provided as 60% TG
formulation (TG60); (4) fish
oil 4 g/day of combined EPA
and DHA provided as ethyl
esters (EE) (i.e., 0% TG).
Examine the changes in serum
concentrations of four
subclasses of LDL particles as
well as shifts in LDL phenotype
patterns among
hypertriglyceridemic adults
EPA + HA supplementations significantly
reduce TG modestly increased LDL-C
(26 ± 4 and 13 ± 3%, p < 0.0001)
LDL1, DL2, LDL3 concentrations changes
were a l significant (p < 0.05).
12 weeks
Schmidt
et al. (2012)
20 N/A Controlled,
parallel group
intervention
study
Fish oil Two groups: normo- and
dyslipidemic men both
supplemented with 6 fish oil
capsules per day
Investigate n-3 fatty acids effects
on lipid expression of
metabolism-related genes
Up-reg lation of peroxisome proliferator-
activa d receptor a (PPARa) in dyslipidaemic
patien undergone n-3 fatty acids
supple entation; enhanced lipoprotein
lipase mediated catabolism of VLDL and
reduce VLDL production by repression of
apo C and apo B expression. Down
regula on of Apo CII expression by n-3 fatty
acids pplementation. Triacylglycerols
cleara ce improved in treated patients.
Reduc d mRNA expression of MOGAT3,
MOGA 2 and DGAT1, (genes involved in
triacyl lycerols synthesis) in n-3 fatty acids
supple ented patients. Down-regulation of
LDL re eptor
12 weeks
Kong et al.
(2004)
91 N/A Randomized,
placebo-
controlled trial
Berberine Two groups: (1) berberine; (2)
placebo
Berberine effects in
dyslipidaemia
Berber e reduced serum cholesterol by 29%,
TG by 5% and LDL-C by 25%
3 months
Lee et al.
(2013)
51 18–80 Randomized,
open-label,
multicenter,
parallel groups,
phase IV study
Omega-3 fatty
acids
Patients were randomized to
omega-3 fatty acid 4, 2 g, or
no drug while continuing
statin therapy
Omega-3 fatty acids effects on
lipids
LDL si e and TG levels’ changes were greater
in pat nts undergone 4 g omega-3 fatty acid
assum tion than no drug group (2.8 ± 3.1% vs
2.3 ± 3 %, p = 0.024; 41.0 ± 24.1% vs
24.2% ± 31.9%, p = 0.049)
8 weeks
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J O U R N A L O F F U N C T I O N A L F O O D S 6 ( 2 0 1 4 ) 1 1 –3 2 23nutraceuticals into two categories: traditional and non-tradi-
tional. The first set includes all the substances naturally
contained in foods, not changed by biotechnological
techniques, industrial improvements and/or de novo
synthesis. On the opposite side, we include non-traditional
nutraceuticals that are externally added to the foods by
bio-engineering actions.4. Nutraceutical actions in cardiovascular
diseases
Nutraceuticals are effectively able to reduce the burden of the
atherosclerosis process and coronary heart disease develop-
ment as already demonstrated in the literature (Ciccone
et al., 2013; Garcia-Rios et al., 2013; Giordano et al., 2012;
Kukongviriyapan et al., 2012; Kumar et al., 2012; Mitjavila &
Moreno 2012; Raatz et al., 2013; Sheikholeslami Vatani &
Ahmadi KaniGolzar, 2012; Voloshyna, Hussaini, & Reiss,
2012; Zhang et al., 2013). The main mechanisms that explain
such a positive action on the cardiovascular system are not
well understood. Carotenoids, the fat-soluble pigments pro-
duced by plants and microorganisms and highly present in
fruits, vegetables, seaweeds and some seafoods and a funda-
mental component of Mediterranean foods, are already
known to decrease the incidence and prevalence of cardiovas-
cular events, perhaps by means of their antioxidant action on
free radicals or by acting as anti-inflammatory molecules (i.e.,
by modulating the lipoxygenase enzyme activity) (Giordano
et al., 2012). Izzo et al. (2010) found amelioration in calculated
Framingham Risk Score in patients suffering from metabolic
syndrome and undergoing nutraceutical administration. This
result supports the hypothesis about the use of nutraceuticals
in primary cardiovascular prevention protocols to reduce the
overall burden of cardiovascular disease morbidity and mor-
tality. Nevertheless, further studies are needed to implement
the actual findings associated with this hypothesis.5. Nutraceutical effects on dyslipidaemia:
action mechanisms
Nutraceuticals play a peculiar role in ameliorating human
dyslipidaemia (Marazzi et al., 2011; Sirtori et al., 2009). The ex-
act pathophysiological mechanism is still unknown. Func-
tional food ingredients can act on several biochemical
pathways able to influence lipid disorders in the human body.
Physicians have attempted to identify the mechanisms
responsible for nutraceuticals actions (Baiges et al., 2010;
Chen et al., 2012; Kato et al., 2009; Quesada et al., 2009,
2012). The benefits from red wine consumption (i.e., the
‘‘French paradox’’) (Renaud & de Lorgeril, 1992) are already
known and are ascribed to its resveratrol and polyphenol
contents.
Resveratrol (trans-3,4 0,5-trihydroxystilbene) is a phyto-
alexin produced by more than 70 plant species, whose major
concentrations are detected in grapes, berries, peanuts/pista-
chios (Tokusoglu, Unal, & Yemis, 2005), and red wine (Augu-
stin, Sanguansri, & Lockett, 2013; Maier-Salamon et al.,
2013). According to Zamora-Ros et al. (2008), a rough estima-
tion of resveratrol content in common foods indicates that
Fig. 2 – Nutraceuticals’ classification.
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(0.847 mg/100 g) and itadori tea (0.974 mg/100 g), followed by
wine, grapes, grape juice and peanut butter (range from 0.08
to 0.547 mg/100 g) and peanuts, pistachios and berries
(0.01 mg/100 g).
Chen et al. (2012) hypothesised the role of resveratrol in
counteracting hypercholesterolaemia. They fed mice a hyper-
cholesterolaemic diet and resveratrol (200 mg/kg/day) for
8 weeks, observing a reduction in main serum lipid parame-
ters. The inner mechanism underlying such an effect appears
to involve cholesterol 7a-hydroxylase (CYP7A1), which is an
enzyme able to mediate the conversion of cholesterol in 7a-
hydroxycholesterol and, subsequently, in cholic acid. Bile
acids genesis contributes to the elimination of cholesterol
from plasma. Chen et al. (2012) demonstrated increased
CYP7A1 mRNA transcription, protein production and activity.
In particular, CYP7A1 increased liver X receptor alpha (LXRa)
activation. This nuclear receptor mediates transcriptional
up-regulation of CYP7A1 by binding to an LXR regulatory ele-
ment in the CYP7A1 promoter (Chen et al., 2012). Thus, resve-
ratrol enhances the metabolism of lipids, and this action
ameliorates hypercholesterolaemia in experimental models.
Nevertheless, a recent meta-analysis from Sahebkar (2013 in
press) revealed no effect of resveratrol on dyslipidaemia in
human models. The blood concentrations of every lipid
parameter were not affected by the intake of such a com-
pound, contradicting the previous experimental model re-
sults from Chen et al. (2012). This may be attributable to the
metabolism of resveratrol in human body that results in small
final bioavailability in tissues. An analysis performed by
Sahebkar (2013 in press) outlined that no dose-response rela-
tionship or durations of supplementation affected the plasma
concentrations of resveratrol. The hepatic first-pass metabo-
lism greatly reduces its plasma concentrations, and its
metabolites appear not to succeed in reaching good and opti-
mal concentrations in blood. Thus, resveratrol has been sup-
posed to exert a positive role in humans via down-regulatingproinflammatory conditions or by inhibiting LDL oxidation.
Studies are needed to obtain definite results in regard to this
issue.
The polyphenols contained in mulberry leaf appear to cor-
roborate the results from studies about resveratrol (Wu et al.,
2013 in press). They appear to effectively reduce liver fatty
acid storage and may be counteracting the activity of
enzymes involved in lipid creation, such as fatty acid synthe-
tase, acetyl-CoA carboxylase, or 3-hydroxy-3-methylglutaryl-
CoA reductase. Theaflavins, the major polyphenols in black
tea, have been demonstrated to have lipid-lowering effects
(Jin et al., 2013). Furthermore, Gunathilake, Wang, and Vasan-
tha Rupasinghea (2013) recently demonstrated that a poly-
phenol-rich fruit-based functional beverage was able to
significantly lower liver cholesterol and total and non-HDL-
cholesterol levels in spontaneously hypertensive rats fed a
cholesterol-rich diet.
Water-insoluble fish proteins (IFP) from Alaska Pollock
(Theragra chalcogramma) have been considered as optimal
nutraceuticals in dyslipidaemia management. Kato et al.
(2009) administered such compounds in ovariectomised rats
fed a cholesterol-free diet. The results indicated that IFPs
were able to increase CYP7A1 activities. Furthermore, IFPs in-
creased bile acids in intestine and thus increased faecal
excretion of cholesterol. The 3-hydroxy-3-methylglutaryl-
CoA reductase mRNA levels were decreased by IFPs, providing
a further genetic mechanism able to explain the overall
reduction in plasma cholesterol by means of IFPs (Kato
et al., 2009).
Grape seed reduces lipid plasma levels (Quesada et al.,
2012). One of its components, i.e., proanthocyanidins (poly-
phenols widespread in other compounds of human diet), ap-
pear to play the major role in this process. Proanthocyanidins
act on triacylglycerol levels by reducing their concentration in
chylomicrons and very low-density lipoprotein (VLDL). The
hypothesis is that proanthocyanidins can reduce the secre-
tion of chylomicrons and VLDL, and this action reduces the
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that grape seed proanthocyanidin extracts can primarily im-
prove the activity and expression of carnitine palmitoyltrans-
ferase 1a (CPT-1a), a mitochondrial enzyme that is
fundamental in long-fatty acids metabolism, which, in turn,
results in reduced triacylglycerol formation and thus reduced
VLDL and chylomicrons concentrations. Furthermore, pro-
anthocyanidins reduce hepatic CD36 action, a protein in-
volved in fatty acids uptake by the liver. Its lower activity
decreases the availability of fatty acids for VLDL lipid con-
tents, which thus reduces the levels of plasma triacylglycerols
(Quesada et al., 2012). Proanthocyanidins may modulate tran-
scription of genes involved in VLDL synthesis. In fact, tran-
scription factor sterol regulatory element-binding protein 1
(SREBP1), microsomal transfer protein (MTP) and diacylglyc-
erol O-acyltransferase 2 (DGAT2) are all repressed by grape
seed proanthocyanidin extracts. These are all fundamental
in production and genesis of VLDL and thus in triacylglycerol
synthesis and secretion in the blood. The reduction in their
transcription process leads to reduction of dyslipidaemia in
rats (Baiges et al., 2010; Quesada et al., 2009).
Curcumin, extracted from Curcuma Longa, is able to pre-
vent macrophage transformation in foam cells (Zhao et al.,
2012) by inhibiting scavenger receptor class A, a membrane
protein able to induce internalisation of oxidised LDL in mac-
rophages and initialise foam cells transformation. Further-
more, it promotes up-regulation of ATP-binding cassette
transporter A1, which is a protein involved in cholesterol ef-
flux from macrophage foam cells to apo-AI.
Furthermore, Rahimi-Ardabili et al. (2012) recently demon-
strated that zinc can enhance paraoxonase enzyme activity in
patients on haemodialysis (paraoxonase activity significantly
increased [p = 0.02] in zinc-treated group rather than con-
trols). Paraoxonases are enzymes located on HDL that are in-
volved in the reduction of cardiovascular disease incidences
via a suggested role in preventing LDL oxidation (Li, Liu, &
Liang, 2003). Thus, they reduce the first moments of athero-
sclerotic process development, avoiding LDL-oxidation. This
could be another fundamental mechanism by which nutra-
ceuticals and functional food ingredients can prevent the
negative effects of dyslipidaemia on the cardiovascular
system.
Fish oil is safely employed in dyslipidaemia treatment.
Fish oil is defined in the British Pharmacopoeia (2012 online)
as ‘‘Purified, winterised and deodorised fatty oil obtained from fish
of families such as Engraulidae, Carangidae, Clupeidae, Osmeridae,
Scombridae (except the genera Thunnus and Sarda) and Ammodyti-
dae (type I) or from the genera Thunnus and Sarda within the family
Scombridae (type II)’’. It contains large amounts of unsaturated
fatty acids, above all omega-3 fatty acids (eicosapentaenoic
[EPA] and docosahexaenoic [DHA] acid), which are already
known to exert protective effects on the cardiovascular
system and, therefore, on the cardiovascular risk profile of
individuals (Ciccone et al., 2013; Kris-Etherton et al., 2002;
Stone, 1996). In particular, omega-3 fatty acids supplementa-
tion has hypotriglyceridaemic effects. Their use reduces
triacylglycerol levels from 25% to 30%, although they can in-
crease the serum concentrations of LDL cholesterol (Kris-
Etherton et al., 2002). Physicians have attempted to explain
the molecular mechanisms involved in the hypotriglyceridae-mic effects of fish oil and its omega-3 fatty acid content.
Schmidt et al. (2012) identified up-regulation of peroxisome
proliferator-activated receptor a (PPARa) in dyslipidaemic
patients receiving n-3 polyunsaturated fatty acids (PUFA)
supplementation: the administration of these latter
compounds enhanced lipoprotein lipase (LPL)-mediated
catabolism of VLDL and reduced VLDL production by repress-
ing apo CIII and apo B expression. Such an action enhances
the hypotriglyceridaemic effects of these compounds. Apo
CII (a regulator of lipoprotein lipase activation) expression
was down-regulated in n-3 PUFA supplemented patients.
Therefore, triacylglycerols clearance was improved in treated
patients. In addition, reduced triacylglycerols synthesis was
the result of lower mRNA expression of MOGAT3, MOGAT2
and DGAT1, which are the three fundamental genes involved
in triacylglycerol synthesis. Nevertheless, an increased VLDL
conversion to LDL and down-regulation of LDL receptor in
dyslipidaemic patients treated with fish oil supplementation
could be detected (Schmidt et al., 2012). In addition,
ankaflavin, a yellow pigment isolated from Monascus-
fermented product, appears to modulate the action of
PPAR-c and, therefore, lipid and glucose metabolism (Hsu
et al., 2013).
Other nutraceutical and functional food ingredients can
exert a role in controlling lipid metabolism (Kwok, Li, Cheng,
et al. 2013; Srinivasan & Pari 2013), but further trials are
needed to corroborate the experimental results.6. Nutraceutical role in dyslipidaemia:
experimental indications
Many studies have evaluated the potential role of nutraceuti-
cals in the prevention of dyslipidaemia both in animal models
(Alshatwi et al., 2011; Chen et al., 2008; Dvir et al., 2009; Huang
& Lin, 2012a, 2012b) and in humans (Becker et al., 2009; Casas-
Agustench et al., 2012; Demonty et al., 2006; Dulin et al., 2006;
Garaiova et al., 2013; Gonc¸alves et al., 2006; Guardamagna
et al., 2011; Izzo et al., 2010; Maki et al., 2012; Marazzi et al.,
2011; Pa´rraga et al., 2011; Qin et al., 2009; Rayman et al.,
2011; Sirtori et al., 2009; Tome´-Carneiro et al., 2012; Weinga¨rt-
ner, Bo¨hm, & Laufs, 2009; Wofford et al., 2012; Wong et al.,
2010; Zhao et al., 2011).
Tome´-Carneiro et al. (2012) managed a triple-blind, ran-
domised, placebo-controlled trial in 75 patients consuming
resveratrol-enriched grape extract, grape extract alone, or
placebo for at least 6 months. Resveratrol-enriched grape ex-
tract induced a significant decrease in the low-density lipo-
protein (LDL) cholesterol, apoB, oxidised LDL and oxidised
LDL/apoB ratio (LDLc, 4.5%, p = 0.04; 9.8%, p = 0.014;
20%, p = 0.001; 12.5%, p = 0.000, respectively) compared
with placebo and grape extract groups. Considering the
homogenous consumption of statins by all individuals en-
rolled in the three groups, these data revealed impressive re-
sults: resveratrol reduces hypercholesterolaemia, and, more
importantly, it reduces the overall burden of oxidation of lip-
ids and thus can be safely adopted in the primary prevention
of cardiovascular disease in association with statins.
Anthocyanins, water-soluble pigments widespread in the
plant kingdom, influence LDL- and high density lipoprotein
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nin supplements on serum lipid profile was evaluated in dysl-
ipidaemic patients by Qin et al. (2009). They observed a
significant reduction in LDL cholesterol concentrations in
the berry-derived anthocyanin supplement group after
12 weeks of treatment [13.6% (95% CI: 10.1% to 17.1%)],
whereas the placebo group displayed an increase in LDL cho-
lesterol [0.6% (95% CI: 4.1% to 5.2%)]. The difference between
groups was significant (p < 0.001) and was related to the inhi-
bition of cholesteryl ester transfer protein (Qin et al., 2009).
Thus, dyslipidaemic patients could benefit from such com-
pounds to ameliorate their lipid state and their consequential
cardiovascular risk profile.
An interesting work about this latest subject comes from
Becker et al. (2009). Although limited by a small sample size
(only 62 patients involved), this research attempted to evalu-
ate the influence of red yeast rice on plasma lipids in patients
suffering from statins discontinuation. After a 24-week obser-
vational period, physicians observed a 21.3% decrease in LDL
cholesterol, which was a significant decrease as compared
with the placebo group (8.7%, p = 0.011). The same results
were obtained with total cholesterol levels (14.9 ± 15.9% vs
5.3 ± 11.4%, p = 0.016). Nevertheless, the question about the
lipid-lowering properties of red yeast rice is complex. Red
yeast rice was already described in the Chinese Tang Dynasty
in 800 AD, where it was used as herbal medication (Becker
et al., 2008). It is obtained by fermenting the yeast Monascus
purpureus over red rice. The process generates substances
called ‘‘monacolins’’ whose major characteristic is the inhibi-
tion of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Therefore, they are able to negatively act on lipid formation
in the same manner as statins. In particular, monacolin K is
the same substance synthetically isolated from Aspergillus ter-
eus and approved for pharmacological treatment of dyslipida-
emia with the name lovastatin. Such considerations reveal
that red yeast rice is a real functional food that is able to re-
duce lipid levels because of its statin contents. Thus, red yeast
rice consumption can be compared with the daily intake of
synthetically prepared statins. Becker et al. (2008, 2009) out-
lined that they adopted levels of red yeast rice containing a
monacolin K (i.e., lovastatin) dose that was inferior to those
of commercial tablets of the statin. This is partially true be-
cause the bioavailability of lovastatin contained in red yeast
rice is higher than that coming from the intake of lovastatin
tablets (Chen et al., 2013). Nevertheless, the normal side ef-
fects of statins appear to be reduced by red yeast rice (Becker
et al., 2008, 2009), perhaps due to the presence of other com-
pounds in the red yeast rice not fully discovered, and are able
to synergistically reduce lipids levels with monacolin K,
resulting in the substance not reaching toxicity levels. It has
been supposed that adding selenium to yeast could further
positively affect lipid profile, although the data coming from
international studies (Rayman et al., 2011) should be better
addressed and confirmed before full statements are drawn
about this subject.
Nutraceutical and functional food ingredients can be
added to common pharmacological treatments for dyslipida-
emia, such as statin therapy, to improve and positively influ-
ence lipid profile by combining the effects of drug therapy and
those of nutraceuticals. Furthermore, they can be consideredas a helpful tool when standard therapy cannot be adopted
because of intolerance. That is, they are not a total substitute
for all well-standardised pharmacological treatments but can
surely improve the outcome of the patients suffering from li-
pid disorders.
Soy milk and its derivatives in the common diet (Sirtori
et al., 2009; Wofford et al., 2012; Wong et al., 2010) can effec-
tively enhance the therapeutic goals of pharmacological treat-
ment of dyslipidaemias. Soymilk significantly reduces plasma
concentrations of all lipids (total cholesterol, LDL-cholesterol
and triacylglycerols), with an average of 2% decrease in total
and LDL cholesterol as compared with carbohydrate or milk
protein administration and a mean 3.6% reduction in total/
HDL cholesterol ratio (Wofford et al., 2012). Wong et al. (2010)
confirmed such results and reported a reduction of approxi-
mately 8–10 mg/dL in LDL cholesterol when soy was added
to prebiotics. The LDL/HDL cholesterol ratio was also affected
in a negative manner: soy plus prebiotics could effectively re-
duce this ratio, whichmeans a reduction in the cardiovascular
risk profile of individuals (Wong et al., 2010).
As many studies (Casas-Agustench et al., 2012; Demonty
et al., 2006; Garaiova et al., 2013; Gonc¸alves et al., 2006; Guarda-
magna et al., 2011; Maki et al., 2012; Pa´rraga et al., 2011;
Weinga¨rtner et al., 2009; Zhao et al., 2011) have already indi-
cated, plant sterols are able to actively influence lipid profile.
The mean LDL-cholesterol reduction after consumption of
plant sterol-supplemented foods ranges from 5.9% to 10.4%
(Casas-Agustench et al., 2012). Thus, these nutraceuticals
effectively improve hypercholesterolaemia. Although the
mechanisms of action of such compounds is not fully known,
they appear to be able to selectively act on LDL-cholesterol for-
mations and, to someextent, on triacylglycerol concentrations
in the blood,whereas little or noactionhadbeenobservedwith
HDL-cholesterol (Demonty et al., 2006; Gonc¸alves et al., 2006;
Maki et al., 2012). An interesting study byMaki et al. (2012) indi-
cated the difference in response of approximately 4.9%
(p = 0.002) in LDL-cholesterol when plant sterols were intro-
duced into the diet compared with the placebo. This result
was associatedwith a difference in response of approximately
3.6% (p = 0.008) in non-HDL-cholesterol (Maki et al., 2012).
Khandelwal et al. (2013) reported no influence of fish-oil ome-
ga-3 PUFAs (2 g/day) on LDL and non-HDL cholesterol levels,
whereas plant sterols appeared to succeed in lowering LDL
and non-HDL cholesterol levels by 4.5% and 7.9%, respectively.
Fish oil and n-3 fatty acids deserve particular mention in
this connection. Their role in dyslipidaemia has been evalu-
ated in several studies. Triacylglycerols appear to be the pre-
ferred target of the action of fish oil and n-3 fatty acids
(Schmidt et al., 2012). Bremer et al. (2013 in press) considered
adult (aged 12–20 years) rhesus monkeys fed a high-fructose
diet or a high-fructose diet plus 4 g fish oil (16% EPA/11%
DHA)/day for 6 months. Fasting triacylglycerols and apo C3
concentrations were significantly lower in the fish oil group
as compared with controls (p = 0.005). Triacylglycerols and to-
tal cholesterol plasma concentrations tended to decrease in
obese KKAy mice fed fish oil (Wakutsu et al., 2012). The statis-
tical trend was maintained in the liver where triacylglycerols
and total cholesterol continued to reach lower levels in the fish
oil group than controls (Wakutsu et al., 2012). The reason for
similar results appears to lie in the reduced expression of fatty
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trols, whereas no effect could be detected related to 3-hydro-
xy-3-methylglutaryl coenzyme A reductase mRNA among
groups (Wakutsu et al., 2012). Effectively, it is known that fish
oil can slightly increase LDL cholesterol. Thus, if one combines
fish oil with statin therapy, a beneficial effect on triacylglyce-
rols blood concentrations can be observed, followed by a par-
allel decrease in LDL levels. Huff, Telford, and Barrett (1992)
observed thatminiature pigs fed fish oil plus lovastatin had re-
duced VLDL and LDL apo B concentrations, primarily due to
lower production rates. Nevertheless, the use of icosapent
ethyl, a high-purity prescription form of eicosapentaenoic
acid ethyl ester appears to overcome the limitations of normal
fish oil and omega-3 fatty acids with LDL particles. Bays et al.
(2012) demonstrated that, in fact, a reduced total LDL particle
concentration (IDL particles, small LDL particles, and large
LDL particles) of approximately 16.3% (p = 0.0006), whereas
the small LDL particle concentrations were reduced by
approximately 25.6% (p < 0.0001) and 12.8% (p = 0.0274) when
administering 4 and 2 g/day of icosapent ethyl, respectively.
A good idea on the feasible application of nutraceuticals
comes from Guardamagna et al. (2011). They attempted to ex-
plore the influence of plant sterols on hypercholesterolaemia
in children suffering from primary hyperlipidaemia. In their
open-label research, they enrolled 32 children with heterozy-
gous familial hypercholesterolemia (FH), 13 children with
familial combined hyperlipidemia (FCH) and 13 children with
undefined hypercholesterolemia (UH). After 12 weeks of treat-
mentwithaplant sterol–enrichedyoghurt, the resultswerepo-
sitive. The total cholesterol was significantly reduced from
baseline in each group (FH: 7.55 ± 1.09 mmol/L at baseline vs
6.90 ± 1.06 mmol/L after treatment, p < 0.05; FCH:
5.90 ± 0.65 mmol/L at baseline vs 5.20 ± 0.75 mmol/L after
treatment, p < 0.05; UH: 6.15 ± 0.83 mmol/L at baseline vs
5.35 ± 0.93 mmol/L after treatment, p < 0.005), as well as LDL-
cholesterol (FH: 5.61 ± 1.06 mmol/L at baseline vs 5.04 ±
1.06 mmol/L after treatment, p < 0.005; FCH: 3.96 ± 0.57 mmol/
L at baseline vs 3.34 ± 0.70 mmol/L after treatment, p < 0.005;
UH: 4.11 ± 0.93 mmol/L at baseline vs 3.36 ± 0.70 mmol/L after
treatment, p < 0.005). These results arevery important because
of the poor tools that physicians have when treating children
diseases. Garaiova et al. (2013) corroborate the evaluations of
Guardamagna et al. (2011) by outlining that the early adminis-
tration of nutraceuticals in hypercholesterolaemic children
could really improve their lipid levels.7. Nutraceuticals versus lipid lowering drugs
in dyslipidaemia treatment
Nutraceuticals reduce dyslipidaemia burden. This action is
fundamental when considering patients who are intolerant
to statins although suffering from severe lipid disorders or
whose statin treatment is not able to obtain good results.
Nutraceuticals could be safely adopted in these individuals
to prevent dyslipidaemia development.
Because of their direct reductive action on triacylglycerols,
fish oil supplementation has always been considered for
hypertriacylglycerolaemic states to improve lipid profile
(Bremer et al., 2013; Schmidt et al., 2012). Nevertheless, it isalready known that they are able to slightly increase LDL par-
ticle concentrations (Bremer et al., 2013; Schmidt et al., 2012).
In a double-blind, parallel design, placebo controlled trial, 42
patients underwent 12 weeks of administration of 4 g/day
omega-3 fatty acids (i.e., eicosapentaenoic acid and docosa-
hexaenoic acid). Oelrich, Dewell, and Gardner (2013) observed
a reduction in serum triacylglycerols of 26 ± 4% (p < 0.0001)
and an increase in total LDL cholesterol of 13 ± 3%
(p < 0.0001). For this reason, it has been supposed a combina-
tion therapy of fish oil supplementation and statins in which
the former decreases triacylglycerols and increase HDL and
the latter acts on LDL particles by reducing their serum con-
centration and cholesterol content would be useful. Chan
et al. (2002) and Lee et al. (2013) confirmed such consider-
ations by demonstrating a better lipid profile of patients suf-
fering from dyslipidaemia when fish oil supplementation
was added to standard statin therapy. Nevertheless, a recent
work by de Lorgeril et al. (2013) indicated some doubts about
such combined treatments. According to the authors, omega-
3 supplementation and statins can negatively interact with
each other, leading to a reduction in the final action on dyslip-
idaemia. Icosapent ethyl can potentially reduce the need for
statins, as it has been demonstrated to actively reduce both
triacylglycerols and total LDL particle (IDL, small LDL, large
LDL) concentrations (Bays et al. 2012). Nevertheless, further
studies are needed to confirm these findings.
Pectin (30 g/day), polyphenols (20 g/day), and phytosterols
(6 g/day) have demonstrated comparable lipid lowering ef-
fects as lovastatin in hypercholesterolaemic swine (Metzger,
Barnes, & Reed, 2009). Some authors (Schneider et al., 2011)
have proposed edible mushrooms as good foods endowed
with lipid-lowering properties. Their levels of n-3 fatty acids
and, additionally, mevinolin (lovastatin) may explain the ef-
fects of such natural foods on lipids.
Berberine is a novel natural compound able to reduce
plasma lipids. It is an alkaloid derived from Huanglian (Coptis
chinensis), and its chemical structure is a benzyltetrahydr-
oxyquinoline (Kong et al., 2004). Its administration deeply re-
duced serum cholesterol by increasing LDL receptor mRNA
expression independent of circulating cholesterol by stabilis-
ing the post-transcriptional products of the gene involved in
LDL receptor mRNA genesis (Kong et al., 2004). This finding
is truly important because of the discovery of a substance that
acts with a different mechanism than statins. Thus, statins
and berberine could be combined to achieve a better control
of LDL cholesterol levels in dyslipidaemic patients. Kong
et al. (2008) found major efficacy of such a combined therapy
(simvastatin plus berberine) as compared with mono-therapy,
with a LDL cholesterol reduction of 31.8% (p < 0.05 vs berberine
alone, p < 0.01 vs simvastatin alone) and similar results were
observed for total cholesterol and triacylglycerols levels. Thus,
nutraceuticals could be added to standard statin therapy.
According to the literature, this combination is safe for pa-
tients and produces no side effects (Eussen et al., 2010). Even
when patients are intolerant to statins, nutraceuticals can
have a fundamental role in treating dyslipidaemia (Micallef
& Garg, 2009; Sikka et al., 2011; Stock, 2012). Panahi et al.
(2011) demonstrated that Heracleum persicum supplementation
of atorvastatin at 10 mg allowed comparable reduction in lipid
plasma levels to atorvastatin at 20 mg. H. persicum can be
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age and, consequentially, the side effects related to statin
administration (Panahi et al., 2011).
8. Doubt about nutraceutical administration
Despite enthusiastic results reported in the literature, a re-
cent review fromWeingartner et al. (2009) generated concerns
about nutraceuticals in clinical practice as useful compounds
in dyslipidaemia management.
In particular, the authors dealt with the effective role of
phytosterols in dyslipidaemia management and their rela-
tionship with the overall cardiovascular risk burden of indi-
viduals, gathering information coming from literature. Plant
sterols are the main component of plant cell membranes.
Their biochemical structure is tightly related to that of choles-
terol: an extra ethyl group (sitosterol and stigmasterol) or
methyl (campesterol) group at C-24 of the sterol side chain
is responsible for the difference as compared with the choles-
terol chemical formula (Othman, Myrie, & Jones, 2013; Wein-
gartner et al., 2009). The absence of a double bond in the sterol
ring, that is, the saturation of carbon atoms in the sterol ring,
generates the corresponding plant stanols. The role of phy-
tosterols in lipid metabolism has raised questions because
of the uncertainty in the exact mechanisms involved. In par-
ticular, plant sterols and stanols appear to decrease the plas-
ma concentration of cholesterol by reducing its absorption at
the enterocyte level. It is possible that the higher lipophilic
properties of phytosterols displace cholesterol from absorp-
tion. This would reduce the concentration of cholesterol into
chylomicrons, and, therefore, there would be less introduc-
tion of cholesterol with diet (De Smet, Mensink, & Plat,
2012). Furthermore, it would be possible for phytosterols to fa-
vour the excretion of cholesterol from enterocytes to the
intestinal lumen by means of adenosine triphosphate binding
cassette G 5 (ABCG5) and G 8 (ABCG8) transporters (De Smet
et al., 2012). Thus, cholesterol absorption is reduced and,
although the endogenous production rate of cholesterol is in-
creased, the net result is a final reduction in plasma concen-
tration of cholesterol (Jones & AbuMweis, 2009). Phytosterols
can properly be adopted as lipid lowering nutraceuticals,
and can be safely added to other pharmaceuticals. Thus, their
ability to reduce cholesterol concentration in plasma also
indicates an ability to reduce cardiovascular risk in patients.
Nevertheless, Weingartner et al. (2009) had doubts about the
real effect of phytosterols on cardiovascular risk. Phytosterols
can favour LDL uptake in vessels and tissues, as
demonstrated by xanthomatosis in patients suffering from
sitosterolaemia. Thus, although they reduce LDL plasma con-
centrations, they cannot prevent atherosclerosis develop-
ment. Furthermore, plant sterols can be incorporated in cell
membranes altering their function and structure, which in-
duces an unstable condition that enhances organ damage
(Weingartner et al., 2009).
Dulin et al. (2006) evaluated the efficacy of sugar cane-de-
rived policosanol in healthy adults with mild hypercholester-
olemia, but they failed to demonstrate a reduction in total
and LDL-cholesterol and in triacylglycerols in this type ofpatients. Thus, policosanol cannot be considered as being
able to influence the cardiovascular risk profile of individuals.
Policosanols are long-chain fatty alcohols ranging from 24 to
34 carbons in length. As Jones, Kassis, and Marinangeli
(2009) already indicated, literature data about policosanol effi-
cacy on lipids is quite confusing and unclear. They revealed
that although a few reports have highlighted the possible role
of policosanols in reducing LDL cholesterol by suppressing its
biosynthesis, when translating such experimental results to
human studies, the endpoints were not reached. This limits
the full consideration of such compounds for adoption in
dyslipidaemic patients as lipid-level controllers.
Overall, the role of nutraceuticals in cardiovascular risk
protection is still under debate. Several trials are needed to
establish their exact real role for such a purpose.
9. Future directions in functional food and
nutraceutical implementation
Ongoing trials (Pa´rraga et al., 2011) intend to elucidate the
influence of sterols and, broadly, of nutraceuticals on lipid
lowering. Surely, functional food and nutraceuticals have
the potential to become the future of primary prevention in
dyslipidaemia treatment in particular and, secondarily, in car-
diovascular disease prevention because of their demonstrated
actions in past studies. Marinangeli and Jones (2013) sup-
posed an important role for them in human diet and cardio-
vascular risk reduction, but, correctly, they noted that such
a role may be greatly increased and become more reliable in
clinical practice with only increased trust by industrial pro-
ducers in these products. The researchers hoped that manu-
facturers will be able to devote resources to nutraceutical
development, but the economic crisis has limited such an
effort.
An ongoing area of focus is the influence of genetics on the
lipid levels of individuals beyond lipid-lowering treatment
(Rudkowska et al., 2013). This is an aspect that should be ta-
ken into account when evaluating and treating a patient.
Although it is too early to introduce genetic evaluation into
clinical practice and treatment guidelines, future studies
should aim first to develop drugs that are able to attack sev-
eral pathway of lipid metabolism. For this purpose, nutraceu-
ticals appear to guarantee the success of such research. As
previously noted (Garcia-Rios et al., 2013; Giordano et al.,
2012; Kukongviriyapan et al., 2012; Li et al., 2003; Mitjavila &
Moreno, 2012; Sheikholeslami Vatani & Ahmadi Kani Golzar,
2012; Voloshyna et al. 2012; Zhang et al. 2013; Zhao et al.
2012), nutraceuticals are able to interact with several bio-
chemical pathways in lipid metabolism, and thus, they have
the potential to overcome the genetic variability of individu-
als. Many features should still be defined such as the exact
mechanisms of action of nutraceuticals, the perfect dosages
to be used in clinical practice, the dose-response relation-
ships, the duration of effects, and other such related features
(Brownawell et al., 2012). Thus, we are still waiting for future
studies to explain the exact pharmacokinetics and pharmaco-
dynamics of nutraceuticals to better adopt these molecules as
therapeutics in dyslipidaemia treatment.
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